WEBULL
WebtradeDownload

Is Structure Therapeutics (GPCR) Undervalued Following New Aleniglipron Data Ahead Of ObesityWeek 2026?

Simply Wall St · 3d ago

Structure Therapeutics (GPCR) is drawing fresh attention after announcing upcoming ObesityWeek 2026 presentations on aleniglipron, its oral GLP-1 candidate, with new ACCESS trial data on dose-ranging and longer term use.

The upcoming ObesityWeek data arrives after a tough stretch for Structure Therapeutics, with the 30 day share price return down 37.11% and the year to date share price return down 67.69%. The 1 year total shareholder return has fallen 21.03% as sentiment around clinical and funding risk has shifted.

Scan beyond Structure Therapeutics and line up other obesity and weight management players with the hand-picked 33 healthcare AI stocks that could sit on your watchlist next.

Structure Therapeutics now trades at a steep gap to both its recent highs and the analyst price target near $105.78. Is that discount pointing to mispricing, or is it simply mirroring the clinical and funding risk now priced in?

Most Popular Narrative: 79% Undervalued

On the widely followed narrative, Structure Therapeutics screens as heavily discounted, with a fair value near $105.78 against a last close of $22.01. This puts a lot of weight on how its obesity pipeline matures over the next few years.

Scaling of oral GLP‑1 use in obesity treatment, with about 1.4 million U.S. patients and roughly 17% market share within months of launch and management expectations that oral agents could reach around half of the market by 2030, supports a long runway for aleniglipron to add incremental revenue and earnings power if it reaches the market. Launch of the ACCOMPLISH‑1 and ACCOMPLISH‑2 Phase III obesity trials, which plan to treat about 4,700 participants at maintenance doses for at least 52 weeks, positions Structure Therapeutics to generate long duration efficacy and safety data that could underpin a commercial profile with scale benefits for revenue and profitability.

See why 1 investors see Structure Therapeutics as 79% undervalued.

Result: Fair Value of $105.78 (UNDERVALUED)

Still, the bullish Structure Therapeutics story can break if obesity trial tolerability stumbles or if intensifying GLP-1 competition keeps investor multiples in check.

Find out about the key risks to this Structure Therapeutics narrative.

Next Steps

With sentiment on Structure Therapeutics clearly split between caution and optimism, move quickly, review the underlying data, and weigh both the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Structure Therapeutics?

Do not stop your research with Structure Therapeutics when a broader watchlist could sharpen your decisions and highlight opportunities that match your own risk and return preferences.